펩티드 합성 시장(제3판) : API 유형별, 펩티드 합성법 유형별, 화학 합성법 유형별, 조업 규모별, 기업 규모별, 지역별 - 동향과 예측(-2035년)

PEPTIDE SYNTHESIS MARKET: OVERVIEW

As per Roots Analysis, the global peptide synthesis market is estimated to grow from USD 4.4 billion in the current year to USD 7.0 billion by 2035, registering a CAGR of 5.2% across the forecast period.

Peptide Synthesis Market: Growth and Trends

Peptides have emerged as an important class of therapeutic candidates, owing to their enhanced metabolic stability, biological target specificity and higher binding affinity compared to small molecules. Regulatory authorities across different regions of the world have approved close to 100 peptide therapeutics for the treatment of chronic diseases, including cancer, chronic pain, diabetes, HIV infection, multiple sclerosis, and osteoporosis.

The expanding pipeline of peptide-based drugs, particularly GLP-1 and GIP receptor agonists for diabetes and obesity, has translated into a sharp rise in demand for peptide API manufacturing. Peptide synthesis, however, remains a technically demanding process, and many developers face a persistent shortage of production capacity. As a result, an increasing share of complex manufacturing work is being outsourced to specialized peptide contract manufacturing organizations, enabling faster time to market and lower capital intensity for drug developers.

In response, established contract manufacturers are expanding solid phase, liquid phase, and hybrid synthesis capacity, upgrading purification infrastructure, and integrating automated and AI-assisted process controls. CordenPharma, PolyPeptide, Cambrex and several other players have announced facility expansions over the past year, reflecting the scale of investment being directed toward closing the manufacturing capacity gap for next-generation peptide therapeutics.

Growth Drivers: Factors Fueling Market Expansion

One of the significant drivers of the market is the rising global prevalence of chronic diseases such as cancer, diabetes and other metabolic disorders. This growing therapeutic need is fueling a larger and more complex peptide R&D pipeline, encouraging drug developers to outsource API production to specialized contract drug manufacturing organizations (CDMOs) for both clinical and commercial supply.

Continuous advancements in peptide synthesis technologies, including refinements to solid phase and liquid phase methods and the emergence of hybrid and microwave-assisted approaches, are improving efficiency, scalability and cost-effectiveness. These innovations are enabling CDMOs to take on more structurally complex projects. CordenPharma's multi-year agreement with Viking Therapeutics to support commercial manufacturing of the GLP-1 / GIP candidate VK2735 illustrates how technological capability is translating directly into large-scale supply commitments.

Market Challenges: Critical Barriers Hindering Progress

Despite strong growth in demand, the market faces several challenges. The manufacturing capacity of peptide producers and CDMOs is struggling to keep pace with the rapidly growing demand for complex, high-volume peptides, particularly GLP-1 analogs, resulting in persistent supply bottlenecks.. Many next-generation peptides involve longer sequences and additional modifications that strain conventional solid phase and liquid phase methods, requiring capital-intensive investment in hybrid and continuous flow platforms that are still gaining commercial adoption.

Additionally, traditional peptide synthesis remains solvent and resource intensive, and the shift toward greener, more sustainable processes requires meaningful process redesign and added cost. Manufacturing capacity also remains geographically concentrated, which leaves the supply chain exposed to regional disruptions and evolving trade policies, including tariff-related uncertainty affecting pharmaceutical imports into the US.

Peptide Synthesis Market: Key Insights

The report delves into the current state of the peptide synthesis market and identifies potential growth opportunities for distribution partners, channel intermediaries, and service integrators. Some key findings include:

• Increasing Capital Investment: More than EUR 900 million was committed by CordenPharma in capacity investment, alongside PolyPeptide's capacity-doubling expansion in Malmo and Cambrex's facility expansion in Waltham, Massachusetts, reflecting sustained capital deployment toward closing the global peptide manufacturing capacity gap.
• Accelerating Market Consolidation: Granules India's acquisition of Senn Chemicals in April 2025 to enter the peptide CDMO space is representative of continued consolidation, as diversified pharmaceutical and generics players seek rapid entry into peptide manufacturing through targeted acquisitions.
• Partnership and Collaboration: Recent agreements, including Hybio Pharmaceutical's product development and manufacturing agreement with iCarbonX Intelligent Peptide and its commercial supply agreement with Sunshine Mandi Pharmaceutical for a semaglutide weight-loss injection, point to growing reliance on outsourced, large-scale peptide API production.
• Green Chemistry as a Differentiator: EUROAPI's collaboration with StrainChem for Sustainable Liquid Phase Peptide Synthesis and Innovate UK's EUR 913,659 investment in sustainable GLP-1 biomanufacturing indicate that sustainability credentials are becoming a differentiating factor in CDMO selection.
• Key Future Opportunities: Global capacity build-out continues to trail demand for high-volume peptides, particularly GLP-1 analogs. The pace at which new capacity comes online is expected to be a key determinant of competitive positioning among CDMOs, making it an important metric for investors to monitor.

Peptide Synthesis Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of API

• Generic APIs
• New Chemical Entities

By Type of Peptide Synthesis Method

• Chemical Synthesis
• Non-Chemical Synthesis

By Type of Chemical Synthesis Method

• Solid Phase Synthesis
• Liquid Phase Synthesis
• Hybrid Phase Synthesis

By Scale of Operation

• Commercial Scale
• Preclinical / Clinical Scale

By Company Size

• Small Companies
• Mid-sized Companies
• Large and Very Large Companies

By Geographical Regions

• North America
• US
• Canada
• Europe
• Belgium
• Switzerland
• UK
• Germany
• Ireland
• Netherlands
• Italy
• France
• Sweden
• Rest of Europe
• Asia-Pacific and Rest of the World
• China
• India
• Japan
• Korea
• Rest of Asia-Pacific and Other Countries

Peptide Synthesis Market: Key Segments

Generic APIs Segment Leads the Peptide Synthesis Market

Based on our market assessment, the generic APIs segment is expected to account for the largest share of the peptide synthesis market. This leadership is primarily driven by patent expirations of first-generation peptide drugs and the comparatively high cost associated with branded therapies, which continues to push developers toward generic peptide API manufacturing.

Chemical Synthesis Method Retains Dominant Share

On the basis of type of peptide synthesis method, the chemical synthesis segment currently holds the largest market share. This dominance is attributed to the widespread adoption of chemical synthesis, driven by its scalability, flexibility, cost-effectiveness, and ease of implementation relative to non-chemical approaches.

Solid Phase Synthesis to be the Cornerstone of Peptide Synthesis

Within chemical synthesis methods, the solid phase synthesis segment holds the highest share of the market. This dominance stems from its numerous advantages, including rapid production of linear peptides, simplified purification, and cost-effectiveness.

The hybrid phase synthesis segment, on the other hand, is likely to grow at a higher CAGR during the forecast period. This growth is primarily attributed to its suitability for the complex and long peptide sequences entering the R&D pipeline. By combining the strengths of solid phase and liquid phase methods, hybrid synthesis offers improved efficiency, yield and cost-effectiveness for next-generation therapeutics that are difficult to manufacture using a single method alone.

Commercial Scale Manufacturing to Retain Dominant Share

Based on scale of operation, the commercial scale segment accounts for the largest market share and this segment will also register higher CAGR during the forecast period. This is mainly attributed to the substantial volumes and high monetary value associated with manufacturing GMP-grade peptide APIs. Long-term commercial supply agreements for marketed therapies generate revenue that significantly surpasses preclinical and clinical scale projects.

Moreover, once a peptide drug receives regulatory approval, manufacturers typically enter into long-term commercial supply agreements with pharmaceutical companies, ensuring stable and recurring revenue streams over several years. The increasing adoption of high-purity synthetic peptides, advancements in large-scale solid-phase peptide synthesis (SPPS) technologies, and continued expansion of manufacturing capacities by CDMOs further strengthen this segment.

Europe Dominates the Market for Peptide Synthesis

According to our market projections, Europe is expected to retain the highest share of global peptide synthesis market revenue. This dominance is attributable to the region's significant share of global manufacturing capacity, a higher number of clinical trials, and a robust innovation ecosystem built on strong academic-industry collaborations.

Belgium is a leading contributor within Europe, supported by its status as a major biotech hub, government incentives for the life sciences, and its strategic location for pharmaceutical logistics. Switzerland is also emerging as a key market, anchored by Bachem's manufacturing footprint and a deeply integrated life sciences ecosystem.

Asia-Pacific Emerges as the Fastest-Growing Regional Market

Asia-Pacific is expected to register the highest CAGR through 2035. This lucrative growth is driven by an expanding regional pharmaceutical market, significant government investment in life sciences, and a cost-effective manufacturing ecosystem supported by lower capital expenditure and skilled labor availability. This growth is being reinforced by regional manufacturers such as WuXi STA, a WuXi AppTec company.

Example Players in Peptide Synthesis Market

• Amneal Pharmaceuticals
• Asymchem
• Aurisco Pharma
• Dr Reddy's Laboratories
• Hybio Pharmaceutical
• JYMed Peptide
• Neuland Labs
• Sinopep-Allsino Biopharmaceutical
• SK Pharmteco
• WuXi STA (a WuXi AppTec company)

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Founder and Owner, Small Company, Germany
• Chief Financial Officer, Small Company, Germany
• Chief Business Officer, Small Company, US
• Senior Director of Scientific Affairs and Technical Marketing, Small Company, US
• Vice President, Peptides, Large Company, Ireland
• Senior Manager, Peptide Business Project Leader, Large Company, Japan
• Chief Scientific Officer, Co-Founder, Small Company, India

PEPTIDE SYNTHESIS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the peptide synthesis market, focusing on key market segments, including type of API, type of peptide synthesis method, type of chemical synthesis method, scale of operation, company size and geographical regions.
• Peptide Synthesis Market Landscape: A detailed assessment of the overall market landscape, featuring information on parameters such as year of establishment, company size, location of headquarters, type of product and API manufactured, scale of operation, type of service offered, synthesis method used, and regulatory certifications held by peptide API contract manufacturers.
• Company Competitiveness Analysis: A benchmarking of peptide API contract manufacturers headquartered in North America, Europe, and Asia-Pacific and Rest of the World, based on relevant competitiveness parameters.
• Company Profiles: In-depth profiles of prominent players engaged in offering peptide API contract manufacturing services, featuring information on their company overview, financial information (where available), service portfolio, manufacturing facilities and capabilities, and recent developments.
• Recent Developments: A detailed analysis of recent partnerships and collaborations, facility expansions, and emerging peptide synthesis technologies, including chemo-enzymatic synthesis, continuous flow technology and green chemistry.
• Clinical Trial Analysis: An analysis of ongoing and completed clinical trials related to peptide therapeutics, based on parameters such as trial phase, trial status, study design, therapeutic area, sponsor type and geography.
• Regional Capability Analysis: An assessment of the regional distribution of peptide API contract manufacturing facilities and capabilities across North America, Europe, and Asia-Pacific and Rest of the World.
• Demand Analysis: An estimate of the annual global demand for peptide API contract manufacturing, segmented by clinical and commercial demand, phase of development, mechanism of action, synthesis method and geography.
• Capacity Analysis: An analysis of the global installed peptide API contract manufacturing capacity, distributed by company size, scale of operation, synthesis method and geography.
• Likely Partners Analysis: An analysis identifying potential strategic partners for peptide API contract manufacturers across North America, Europe, and Asia-Pacific and Rest of the World.
• Make versus Buy Decision Making Framework: A framework to help stakeholders evaluate the decision to develop in-house peptide manufacturing capabilities versus outsourcing to a contract manufacturer, across multiple illustrative scenarios.
• Total Cost of Ownership: An analysis of the total cost of ownership for a peptide API contract manufacturing organization over a twenty-year horizon, distributed by capital and operational expenditure.
• SWOT Analysis: A qualitative analysis of the strengths, weaknesses, opportunities and threats affecting stakeholders in the peptide synthesis market.

Key Questions Answered in this Report

• Which are the leading companies in the peptide synthesis market?
• Which region dominates the peptide synthesis market?
• What are the key trends observed in the peptide synthesis market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by peptide API contract manufacturers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complementary PPT Insights Pack
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Value and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product (GDP)
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross-Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

• 5.1. Executive Summary: Market Landscape
• 5.2. Executive Summary: Market Trends
  • 5.2.1. Recent Developments
  • 5.2.2. Clinical Trial Analysis
  • 5.2.3. Demand and Capacity Analysis
  • 5.2.4. Total Cost of Ownership
• 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Overview of Peptides
  • 6.2.1. Structural Analysis of Peptides
  • 6.2.2. Classification of Peptides
  • 6.2.3. Peptide Synthesis
  • 6.2.4. Emerging Technologies for Peptide Synthesis
  • 6.2.5. Peptide Modification
    • 6.2.5.1. N-terminal Modifications
    • 6.2.5.2. Internal Modifications
    • 6.2.5.3. C-terminal Modifications
    • 6.2.5.4. Other Modifications
  • 6.2.6. Peptide Purification
  • 6.2.7. Peptide Purity Guidelines
• 6.3. Overview of Contract Manufacturing
  • 6.3.1. Need for Outsourcing in the Peptide Manufacturing Industry
  • 6.3.2. General Considerations for Selecting a CMO Partner
  • 6.3.3. Advantages of Outsourcing Manufacturing Operations
  • 6.3.4. Risks and Challenges Associated with Outsourcing of Peptide API Manufacturing
• 6.4. Future Perspectives

7. REGULATORY LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Regulatory Scenario: North America
  • 7.2.1. Scenario in the US
    • 7.2.1.1. Overview
    • 7.2.1.2. General Guidelines for Peptide Manufacturing
• 7.3. Regulatory Scenario: Europe
  • 7.3.1. Scenario in Europe
    • 7.3.1.1. Overview
    • 7.3.1.2. General Guidelines
  • 7.3.2. Scenario in the UK
    • 7.3.2.1. Overview
    • 7.3.2.2. General Guidelines for Peptide Manufacturing
• 7.4. Regulatory Scenario: Asia-Pacific
  • 7.4.1. Overview
  • 7.4.2. Scenario in Australia
    • 7.4.2.1. General Guidelines for Peptide Manufacturing
  • 7.4.3. Scenario in China
    • 7.4.3.1. General Guidelines for Peptide Manufacturing
    • 7.4.3.2. Tax-related Modifications in Chinese Pharmaceutical Sector
  • 7.4.4. Scenario in India
    • 7.4.4.1. General Guidelines for Peptide Manufacturing
    • 7.4.4.2. Tax-related Modifications in Indian Pharmaceutical Sector
  • 7.4.5. Scenario in Japan
    • 7.4.5.1. General Guidelines for Peptide Manufacturing
  • 7.4.6. Scenario in South Korea
    • 7.4.6.1. General Guidelines for Peptide Manufacturing
• 7.5. Challenges Associated with Peptide Manufacturing

8. MARKET LANDSCAPE

• 8.1. Chapter Overview
• 8.2. Peptide Synthesis: Overall Market Landscape
  • 8.2.1. Analysis by Year of Establishment
  • 8.2.2. Analysis by Year of Experience of Peptide Synthesis Companies
  • 8.2.3. Analysis by Company Size
  • 8.2.4. Analysis by Location of Headquarters
  • 8.2.5. Analysis by Type of Product Manufactured
  • 8.2.6. Analysis by Type of API Manufactured
  • 8.2.7. Analysis by Scale of Operation
  • 8.2.8. Analysis by Type of Service Offered
  • 8.2.9. Analysis by Type of Peptide Synthesis Method Used
  • 8.2.10. Analysis by Type of Peptide Modification Offered
  • 8.2.11. Analysis by Type of Purification Technology Used
  • 8.2.12. Analysis by Regulatory Certifications and Accreditations
  • 8.2.13. Analysis by Geographical Presence
  • 8.2.14. Analysis by Location of Peptide Synthesis Facilities
• 8.3. List of Custom Peptide Manufacturers

9. COMPANY COMPETITIVENSS ANALYSIS

• 9.1. Chapter Overview
• 9.2. Key Parameters
• 9.3. Methodology
• 9.4. Company Competitiveness Analysis
  • 9.4.1. Peptide Synthesis Companies Headquartered in North America
  • 9.4.2. Peptide Synthesis Companies Headquartered in Europe
  • 9.4.3. Peptide Synthesis Companies Headquartered in Asia-Pacific and Rest of the World

10. COMPANY PROFILES: PEPTIDE SYNTHESIS COMPANIES

• 10.1. Chapter Overview
• 10.2. Peptide Synthesis Companies based in North America
  • 10.2.1. AmbioPharm
    • 10.2.1.1. Company Overview
    • 10.2.1.2. Peptide Synthesis Service Portfolio
    • 10.2.1.3. Peptide Synthesis Facilities and Capabilities
    • 10.2.1.4. Recent Developments and Future Outlook
  • 10.2.2. Creative Peptides
    • 10.2.2.1. Company Overview
    • 10.2.2.2. Peptide Synthesis Service Portfolio
    • 10.2.2.3. Peptide Synthesis Facilities and Capabilities
    • 10.2.2.4. Recent Developments and Future Outlook
  • 10.2.3. CSBio
    • 10.2.3.1. Company Overview
    • 10.2.3.2. Peptide Synthesis Service Portfolio
    • 10.2.3.3. Peptide Synthesis Facilities and Capabilities
    • 10.2.3.4. Recent Developments and Future Outlook
• 10.3. Peptide Synthesis Companies based in Europe
  • 10.3.1. Bachem
    • 10.3.1.1. Company Overview
    • 10.3.1.2. Financial Information
    • 10.3.1.3. Peptide Synthesis Service Portfolio
    • 10.3.1.4. Peptide Synthesis Facilities and Capabilities
    • 10.3.1.5. Recent Developments and Future Outlook
  • 10.3.2. BCN Peptides
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Peptide Synthesis Service Portfolio
    • 10.3.2.3. Peptide Synthesis Facilities and Capabilities
    • 10.3.2.4. Recent Development and Future Outlook
  • 10.3.3. CordenPharma
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Peptide Synthesis Service Portfolio
    • 10.3.3.3. Peptide Synthesis Facilities and Capabilities
    • 10.3.3.4. Recent Developments and Future Outlook
  • 10.3.4. PolyPeptide
    • 10.3.4.1. Company Overview
    • 10.3.4.2. Financial Information
    • 10.3.4.3. Peptide Synthesis Service Portfolio
    • 10.3.4.4. Peptide Synthesis Facilities and Capabilities
    • 10.3.4.5. Recent Developments and Future Outlook
  • 10.3.5. Senn Chemicals
    • 10.3.5.1. Company Overview
    • 10.3.5.2. Peptide Synthesis Service Portfolio
    • 10.3.5.3. Peptide Synthesis Facilities and Capabilities
    • 10.3.5.4. Recent Developments and Future Outlook
• 10.4. Peptide Synthesis Companies based in Asia-Pacific
  • 10.4.1. Auspep
    • 10.4.1.1. Company Overview
    • 10.4.1.2. Peptide Synthesis Service Portfolio
    • 10.4.1.3. Peptide Synthesis Facilities and Capabilities
    • 10.4.1.4. Recent Developments and Future Outlook
  • 10.4.2. Hybio Pharmaceutical
    • 10.4.2.1. Company Overview
    • 10.4.2.2. Peptide Synthesis Service Portfolio
    • 10.4.2.3. Peptide Synthesis Facilities and Capabilities
    • 10.4.2.4. Recent Developments and Future Outlook
  • 10.4.3. Peptide Institute
    • 10.4.3.1. Company Overview
    • 10.4.3.2. Peptide Synthesis Service Portfolio
    • 10.4.3.3. Peptide Synthesis Facilities and Capabilities
    • 10.4.3.4. Recent Developments and Future Outlook
  • 10.4.4. ScinoPharm
    • 10.4.4.1. Company Overview
    • 10.4.4.2. Financial Information
    • 10.4.4.3. Peptide Synthesis Service Portfolio
    • 10.4.4.4. Peptide Synthesis Facilities and Capabilities
    • 10.4.4.5. Recent Developments and Future Outlook
• 10.5. Company Deep Dive: Peptide Synthesis Companies
  • 10.5.1. Amneal Pharmaceuticals
    • 10.5.1.1. Company Details
    • 10.5.1.2. Financial Details
    • 10.5.1.3. SWOT Analysis
    • 10.5.1.4. Strategic Framework
    • 10.5.1.5. Recent Developments and Future Outlook
  • 10.5.2. Asymchem
    • 10.5.2.1. Company Details
    • 10.5.2.2. Peptide Synthesis Service Portfolio
    • 10.5.2.3. Peptide Synthesis Facilities
    • 10.5.2.4. Financial Details
    • 10.5.2.5. SWOT Analysis
    • 10.5.2.6. Strategic Framework
    • 10.5.2.7. Recent Developments and Future Outlook
  • 10.5.3. Aurisco Pharma
    • 10.5.3.1. Company Details
    • 10.5.3.2. Peptide Synthesis Facilities
    • 10.5.3.3. Financial Details
    • 10.5.3.4. SWOT Analysis
    • 10.5.3.5. Strategic Framework
    • 10.5.3.6. Recent Developments and Future Outlook
  • 10.5.4. Dr Reddy's Laboratories
    • 10.5.4.1. Company Details
    • 10.5.4.2. Peptide Synthesis Service Portfolio
    • 10.5.4.3. Peptide Synthesis Facilities
    • 10.5.4.4. Financial Details
    • 10.5.4.5. SWOT Analysis
    • 10.5.4.6. Strategic Framework
    • 10.5.4.7. Recent Developments and Future Outlook
  • 10.5.5. Hybio Pharmaceutical
    • 10.5.5.1. Company Details
    • 10.5.5.2. Peptide Synthesis Service Portfolio
    • 10.5.5.3. Peptide Synthesis Facilities
    • 10.5.5.4. SWOT Analysis
    • 10.5.5.5. Strategic Framework
    • 10.5.5.6. Recent Developments and Future Outlook
  • 10.5.6. JYMed Peptide
    • 10.5.6.1. Company Details
    • 10.5.6.2. Peptide Synthesis Service Portfolio
    • 10.5.6.3. Peptide Synthesis Facilities
    • 10.5.6.4. SWOT Analysis
    • 10.5.6.5. Strategic Framework
    • 10.5.6.6. Recent Developments and Future Outlook
  • 10.5.7. Neuland Labs
    • 10.5.7.1. Company Details
    • 10.5.7.2. Peptide Synthesis Service Portfolio
    • 10.5.7.3. Peptide Synthesis Facilities
    • 10.5.7.4. Financial Details
    • 10.5.7.5. SWOT Analysis
    • 10.5.7.6. Strategic Framework
    • 10.5.7.7. Recent Developments and Future Outlook
  • 10.5.8. Sinopep-Allsino Biopharmaceutical
    • 10.5.8.1. Company Details
    • 10.5.8.2. Peptide Synthesis Service Portfolio
    • 10.5.8.3. Peptide Synthesis Facilities
    • 10.5.8.4. Financial Details
    • 10.5.8.5. SWOT Analysis
    • 10.5.8.6. Strategic Framework
    • 10.5.8.7. Recent Developments and Future Outlook
  • 10.5.9. SK Pharmteco
    • 10.5.9.1. Company Details
    • 10.5.9.2. Financial Details
    • 10.5.9.3. SWOT Analysis
    • 10.5.9.4. Strategic Framework
    • 10.5.9.5. Recent Developments and Future Outlook
  • 10.5.10. WuXi STA (a WuXi AppTec company)
    • 10.5.10.1. Company Details
    • 10.5.10.2. Peptide Synthesis Service Portfolio
    • 10.5.10.3. Peptide Synthesis Facilities
    • 10.5.10.4. Financial Details
    • 10.5.10.5. SWOT Analysis
    • 10.5.10.6. Strategic Framework
    • 10.5.10.7. Recent Developments and Future Outlook

11. RECENT DEVELOPMENTS

• 11.1. Chapter Overview
• 11.2. Partnerships and Collaborations
  • 11.2.1. Partnerships Models
  • 11.2.2. List of Partnerships and Collaborations
  • 11.2.3. Analysis by Year of Partnership
  • 11.2.4. Analysis by Type of Partnership
  • 11.2.5. Analysis by Year and Type of Partnership
  • 11.2.6. Analysis by Company Size and Type of Partnership
  • 11.2.7. Analysis by Scale of Operation
  • 11.2.8. Analysis by Scale of Operation and Type of Partnership
  • 11.2.9. Analysis by Green Chemistry Integration
  • 11.2.10. Most Active Players: Analysis by Number of Partnerships
  • 11.2.11. Analysis by Geography
    • 11.2.11.1. Intercontinental and Intracontinental Agreements
    • 11.2.11.2. Local and International Agreements
• 11.3. Recent Expansions
  • 11.3.1. Expansion Models
  • 11.3.2. List of Recent Expansions
  • 11.3.3. Analysis by Year of Expansion
  • 11.3.4. Analysis by Type of Expansion
  • 11.3.5. Analysis by Year and Type of Expansion
  • 11.3.6. Analysis by Location of Expanded Facility (Region)
  • 11.3.7. Analysis by Location of Expanded Facility (Country)
  • 11.3.8. Recent Expansions: Analysis by Location of Expanded Facility and Type of Expansion
  • 11.3.9. Most Active Players: Analysis by Number of Expansions
  • 11.3.10. Recent Expansions: Analysis by Geography (Country)
• 11.4. Emerging Peptide Synthesis Technologies
  • 11.4.1. Chemo-Enzymatic Peptide Synthesis Technology
  • 11.4.2. Continuous Flow Technology
  • 11.4.3. Green Chemistry

12. CLINICAL TRIAL ANALYSIS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Peptide Therapeutics: Clinical Trials Analysis
  • 12.3.1. Analysis by Trial Registration Year
  • 12.3.2. Analysis by Number of Patients Enrolled by Trial Registration Year
  • 12.3.3. Analysis by Trial Phase
  • 12.3.4. Analysis of Trials by Trial Registration Year and Trial Phase
  • 12.3.5. Analysis by Number of Patients Enrolled by Trial Phase
  • 12.3.6. Analysis by Trial Status
  • 12.3.7. Analysis by Trial Registration Year and Trial Status
  • 12.3.8. Analysis by Therapeutic Area
  • 12.3.9. Analysis by Patient Gender
  • 12.3.10. Analysis by Type of Sponsor / Collaborator
  • 12.3.11. Analysis by Study Design
    • 12.3.11.1. Analysis by Type of Allocation
    • 12.3.11.2. Analysis by Type of Masking
    • 12.3.11.3. Analysis by Type of Intervention
    • 12.3.11.4. Analysis by Trial Purpose
  • 12.3.12. Leading Industry Players: Analysis by Number of Clinical Trials
  • 12.3.13. Analysis by Geography
    • 12.3.13.1. Analysis of Clinical Trials by Geography
    • 12.3.13.2. Analysis of Clinical Trials by Geography and Trial Status
    • 12.3.13.3. Analysis of Patients Enrolled by Geography
    • 12.3.13.4. Analysis of Patients Enrolled by Geography and Trial Status

13. REGIONAL CAPABILITY ANALYSIS

• 13.1. Chapter Overview
• 13.2. Key Assumptions and Methodology
• 13.3. Overall Landscape of Peptide Synthesis Manufacturing Facilities
• 13.4. Peptide Synthesis Capability in North America
• 13.5. Peptide Synthesis Capability in Europe
• 13.6. Peptide Synthesis Capability in Asia-Pacific and Rest of the World

14. DEMAND ANALYSIS

• 14.1. Chapter Overview
• 14.2. Assumptions and Methodology
• 14.3. Peptide Synthesis: Annual Global Demand
  • 14.3.1. Peptide Synthesis: Annual Clinical Demand
    • 14.3.1.1. Clinical Demand for Peptide Synthesis: Analysis by Phase of Development
  • 14.3.2. Peptide Synthesis: Annual Commercial Demand
    • 14.3.2.1. Commercial Demand for Peptide Synthesis: Analysis by Mechanism of Action
  • 14.3.3. Peptide Synthesis: Analysis by Type of Peptide Synthesis Method
  • 14.3.4. Peptide Synthesis: Analysis by Geographical Regions

15. CAPACITY ANALYSIS

• 15.1. Chapter Overview
• 15.2. Key Assumptions and Methodology
• 15.3. Peptide Synthesis: Global Installed Capacity
  • 15.3.1. Analysis by Company Size
  • 15.3.2. Analysis by Scale of Operation
  • 15.3.3. Analysis by Geography
    • 15.3.3.1. Analysis of Peptide Synthesis Capacity in North America
    • 15.3.3.2. Analysis of Peptide Synthesis Capacity in Europe
    • 15.3.3.3. Analysis of Peptide Synthesis Capacity in Asia-Pacific and Rest of the World
  • 15.3.4. Analysis by Company Size and Location of Manufacturing Facility
  • 15.3.5. Analysis by Chemical Synthesis Method Used
• 15.4. Concluding Remarks

16. LIKELY PARTNERS ANALYSIS

• 16.1. Chapter Overview
• 16.2. Assumptions and Key Parameters
• 16.3. Scope and Methodology
• 16.4. Potential Strategic Partners for Peptide Synthesis in North America
• 16.5. Potential Strategic Partners for Peptide Synthesis in Europe
• 16.6. Potential Strategic Partners for Peptide Synthesis in Asia Pacific and Rest of the World
• 16.7. Spider-web Analysis: Potential Strategic Partners

17. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

• 17.1. Chapter Overview
• 17.2. Assumptions and Parameter Definitions
• 17.3. Make versus Buy Decision Making Framework
  • 17.3.1. Scenario 1
  • 17.3.2. Scenario 2
  • 17.3.3. Scenario 3
  • 17.3.4. Scenario 4
• 17.4. Concluding Remarks

18. TOTAL COST OF OWNERSHIP FOR PEPTIDE CONTRACT MANUFACTURING ORGANIZATIONS

• 18.1. Chapter Overview
• 18.2. Key Parameters
• 18.3. Assumptions and Methodology
• 18.4. Total Cost of Ownership for Peptide Synthesis Organization, Y0-Y20
• 18.5. Total Cost of Ownership for Peptide Synthesis Organization: Analysis by CAPEX and OPEX, Y0 and Y20
  • 18.5.1. Total Cost of Ownership for Peptide Synthesis Organization: Analysis by CAPEX, Y0
  • 18.5.2. Total Cost of Ownership for Peptide Synthesis Organization: Analysis by OPEX, Y1-Y20

19. GLOBAL PEPTIDE SYNTHESIS MARKET

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Global Peptide Synthesis Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 19.3.1. Scenario Analysis
    • 19.3.1.1. Conservative Scenario
    • 19.3.1.2. Optimistic Scenario
• 19.4. Key Market Segmentations

20. PEPTIDE SYNTHESIS MARKET, BY TYPE OF API

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Peptide Synthesis Market: Distribution by Type of API
  • 20.3.1. Peptide Synthesis Market for Generic APIs, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 20.3.2. Peptide Synthesis Market for New Chemical Entities, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 20.4. Data Triangulation and Validation

21. PEPTIDE SYNTHESIS MARKET, BY TYPE OF PEPTIDE SYNTHESIS METHOD

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Peptide Synthesis Market: Distribution by Type of Peptide Synthesis Method
  • 21.3.1. Peptide Synthesis Market for Chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 21.3.2. Peptide Synthesis Market for Non-chemical Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 21.4. Data Triangulation and Validation

22. PEPTIDE SYNTHESIS MARKET, BY TYPE OF CHEMICAL SYNTHESIS METHOD

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Peptide Synthesis Market: Distribution by Type of Chemical Synthesis Method
  • 22.3.1. Chemical Synthesis Market for Solid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.3.2. Chemical Synthesis Market for Liquid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 22.3.3. Chemical Synthesis Market for Hybrid Phase Synthesis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 22.4. Data Triangulation and Validation

23. PEPTIDE SYNTHESIS MARKET, BY SCALE OF OPERATION

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Peptide Synthesis Market: Distribution by Scale of Operation
  • 23.3.1. Peptide Synthesis Market for Commercial Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 23.3.2. Peptide Synthesis Market for Preclinical / Clinical Scale, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 23.4. Data Triangulation and Validation

24. PEPTIDE SYNTHESIS MARKET, BY COMPANY SIZE

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. Peptide Synthesis Market: Distribution by Company Size
  • 24.3.1. Peptide Synthesis Market for Very Large and Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.2. Peptide Synthesis Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 24.3.3. Peptide Synthesis Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 24.4. Data Triangulation and Validation

25. PEPTIDE SYNTHESIS MARKET, BY GEOGRAPHY

• 25.1. Chapter Overview
• 25.2. Assumptions and Methodology
• 25.3. Peptide Synthesis Market: Distribution by Geography
  • 25.3.1. Peptide Synthesis Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.1.1. Peptide Synthesis Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.1.2. Peptide Synthesis Market in Canada, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.2. Peptide Synthesis Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.1. Peptide Synthesis Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.2. Peptide Synthesis Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.3. Peptide Synthesis Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.4. Peptide Synthesis Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.5. Peptide Synthesis Market in Ireland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.6. Peptide Synthesis Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.7. Peptide Synthesis Market in the Netherlands, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.8. Peptide Synthesis Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.9. Peptide Synthesis Market in Sweden, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.2.10. Peptide Synthesis Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  • 25.3.3. Peptide Synthesis Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.3.1. Peptide Synthesis Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.3.2. Peptide Synthesis Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.3.3. Peptide Synthesis Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.3.4. Peptide Synthesis Market in Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
    • 25.3.3.5. Peptide Synthesis Market in Other Countries, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
• 25.4. Market Movement Analysis
  • 25.4.1. Penetration-Growth (P-G) Matrix
• 25.5. Data Triangulation and Validation

26. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

• 26.1. Peptide Synthesis Market in North America: Distribution by Type of API
  • 26.1.1. Peptide Synthesis Market in North America for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.1.2. Peptide Synthesis Market in North America for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 26.2. Peptide Synthesis Market in North America: Distribution by Type of Peptide Synthesis Method
  • 26.2.1. Peptide Synthesis Market in North America for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.2.2. Peptide Synthesis Market in North America for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 26.3. Peptide Synthesis Market in North America: Distribution by Type of Chemical Synthesis Method
  • 26.3.1. Chemical Synthesis Market in North America for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.3.2. Chemical Synthesis Market in North America for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.3.3. Chemical Synthesis Market in North America for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 26.4. Peptide Synthesis Market in North America: Distribution by Scale of Operation
  • 26.4.1. Peptide Synthesis Market in North America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.4.2. Peptide Synthesis Market in North America for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates
• 26.5. Peptide Synthesis Market in North America: Distribution by Company Size
  • 26.5.1. Peptide Synthesis Market in North America for Very Large and Large Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.5.2. Peptide Synthesis Market in North America for Mid-sized Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 26.5.3. Peptide Synthesis Market in North America for Small Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27. MARKET OPPORTUNITY ANALYSIS: EUROPE

• 27.1. Peptide Synthesis Market in Europe: Distribution by Type of API
  • 27.1.1. Peptide Synthesis Market in Europe for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.1.2. Peptide Synthesis Market in Europe for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 27.2. Peptide Synthesis Market in Europe: Distribution by Type of Peptide Synthesis Method
  • 27.2.1. Peptide Synthesis Market in Europe for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.2.2. Peptide Synthesis Market in Europe for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 27.3. Peptide Synthesis Market in Europe: Distribution by Type of Chemical Synthesis Method
  • 27.3.1. Chemical Synthesis Market in Europe for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.3.2. Chemical Synthesis Market in Europe for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.3.3. Chemical Synthesis Market in Europe for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 27.4. Peptide Synthesis Market in Europe: Distribution by Scale of Operation
  • 27.4.1. Peptide Synthesis Market in Europe for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.4.2. Peptide Synthesis Market in Europe for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates
• 27.5. Peptide Synthesis Market in Europe: Distribution by Company Size
  • 27.5.1. Peptide Synthesis Market in Europe for Very Large and Large Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.5.2. Peptide Synthesis Market in Europe for Mid-sized Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 27.5.3. Peptide Synthesis Market in Europe for Small Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC AND REST OF THE WORLD

• 28.1. Peptide Synthesis Market in Asia-Pacific and Rest of the World: Distribution by Type of API
  • 28.1.1. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Generic APIs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.1.2. Peptide Synthesis Market in Asia-Pacific and Rest of the World for New Chemical Entities, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 28.2. Peptide Synthesis Market in Asia-Pacific and Rest of the World: Distribution by Type of Peptide Synthesis Method
  • 28.2.1. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.2.2. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Non-chemical Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 28.3. Peptide Synthesis Market in Asia-Pacific and Rest of the World: Distribution by Type of Chemical Synthesis Method
  • 28.3.1. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Solid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.3.2. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Liquid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.3.3. Chemical Synthesis Market in Asia-Pacific and Rest of the World for Hybrid Phase Synthesis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 28.4. Peptide Synthesis Market in Asia-Pacific and Rest of the World: Distribution by Scale of Operation
  • 28.4.1. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.4.2. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates
• 28.5. Peptide Synthesis Market in Asia-Pacific and Rest of the World: Distribution by Company Size
  • 28.5.1. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Very Large and Large Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.5.2. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Mid-sized Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 28.5.3. Peptide Synthesis Market in Asia-Pacific and Rest of the World for Small Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• *Detailed information on Chapter 26-28 is available in the Excel Data Packs shared along with the report

29. SWOT ANALYSIS

• 29.1. Chapter Overview
• 29.2. Strengths
• 29.3. Weaknesses
• 29.4. Opportunities
• 29.5. Threats
• 29.6. Comparison of SWOT Factors

30. ROOTS STRATEGIC RECOMMENDATIONS

31. INSIGHTS FROM PRIMARY RESEARCH

32. REPORT CONCLUSION

33. TABULATED DATA

34. LIST OF COMPANIES AND ORGANIZATIONS

35. CUSTOMIZATION OPPORTUNITIES

36. ROOTS SUBSCRIPTION SERVICES

37. AUTHOR DETAILS